Welcome!

News Feed Item

PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial

Company Aiming to Produce 6-Month Breakthrough Data

NEW YORK, NY--(Marketwired - December 01, 2016) - PharmaCyte Biotech (OTCQB: PMCB) is now one step closer to enrolling patients in a pivotal clinic trial in advanced, inoperable pancreatic cancer after the FDA granted its request for a pre-IND (Investigational New Drug) meeting. A host of oncologists, clinicians and scientists that represent PharmaCyte will now sit down with the U.S. regulatory agency to gain valuable insight that will assist them in filing an Investigational New Drug application -- the final step before patients can be enrolled in a clinical trial.

With PharmaCyte and a team of world-renowned oncologists that includes leading pancreatic cancer expert Dr. Daniel Von Hoff from Translational Drug Development (TD2), Dr. Manuel Hidalgo from Harvard Medical School, and Dr. Matthias Löhr from the Karolinska Institute in Stockholm, Sweden, set to begin a clinical trial in the U.S. and Europe, the FDA's IND process is vital to getting there.

After the IND process runs its course, shareholders should be prepared for what a planned 6-month "hard stop" in the clinical trial could bring in the way of data to the industry. If past performance in earlier clinical trials is any indication, PharmaCyte may be a short time away from what could be a very powerful story for patients with advanced, inoperable pancreatic cancer.

PharmaCyte Could Apply for Breakthrough Therapy Designation

The review of data at the 6-month hard stop could very well lead to PharmaCyte's therapy being given the Breakthrough Therapy Designation by the FDA.

A breakthrough therapy is a drug/therapy:

  • Intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition, and
  • Preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.

According to the FDA, if a drug/therapy is designated as breakthrough therapy, the FDA will speed up the development and review of the drug/therapy.

PharmaCyte's pancreatic cancer therapy has already received the Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA), so if the company can repeat the data from earlier clinical trials, there is a very good chance that PharmaCyte could earn the breakthrough therapy designation from the FDA as well.

There are two areas specifically that could lead to this designation: (1) quality of life and (2) how well PharmaCyte's therapy can shrink inoperable tumors so that they may become operable. In earlier trials, the company's treatment did improve the quality of life and it did show the ability to shrink a pancreatic tumor.

PharmaCyte Addressing an Unmet Medical Need

PharmaCyte has recognized that there is currently an unmet medical need for patients with locally advanced pancreatic cancer (LAPC) that no longer receive any benefit from using the standard of care for the disease (the combination of Abraxane® plus gemcitabine) after 4-6 months of treatment. PharmaCyte expects that its therapy can meet that unmet medical need. The company will enroll those patients whose cancer no longer responds after 4-6 months of treatment using the current gold standard.

In PharmaCyte's clinical trial, about 84 patients with LAPC will be randomly placed into two equal groups.

  • Group 1 will receive just the chemotherapy drug gemcitabine
  • Group 2 will receive PharmaCyte's pancreatic cancer therapy

Those who are familiar with PharmaCyte are also familiar with the impressive data from earlier clinical trials where PharmaCyte's pancreatic cancer therapy dramatically outperformed historical data from gemcitabine. In this upcoming clinical trial the company's therapy will go head-to-head with gemcitabine.

PharmaCyte's pancreatic cancer therapy uses the company's signature live-cell encapsulation technology, Cell-in-a-Box® plus low doses of the FDA-approved chemotherapy drug ifosfamide.

The pinhead-sized, porous capsules (Cell-in-a-Box®), which are placed as close to the pancreatic tumor as possible, are filled with thousands of genetically modified cells that act as a type of "artificial liver" in the sense that these genetically modified cells (about 10,000 cells per capsule) are capable of converting ifosfamide from its normally inactive form into its active cancer-killing form -- just as the enzyme system in a patient's liver would normally do.

By moving the conversion site of the chemotherapy drug (from the liver to the Cell-in-a-Box® capsules) closer to the pancreatic tumor, PharmaCyte's therapy can use a lower dose (1/3 the normal dose) of the chemotherapy drug. The benefit to using a lower dose is that it eliminates the side effects normally seen in patients undergoing chemotherapy, and it is the elimination of these side effects that improved the patient's quality of life in earlier clinical trials.

Improved Imaging Should Allow PharmaCyte to Provide the FDA Better Data

Just as Dr. Von Hoff and Dr. Hidalgo worked together on the clinical trials that brought the industry what is now the gold standard and the FDA approved treatment for advanced pancreatic cancer, Abraxane® plus gemcitabine, so too did Dr. Ron Korn.

Dr. Korn is the Founder, Chairman and Chief Medical Officer of Imaging Endpoints, and just as he was a part of bringing the industry Abraxane® plus gemcitabine, he has signed on to be a part of PharmaCyte's clinical trial as well. This is significant because in earlier clinical trials, PharmaCyte's therapy showed that it could shrink a patients' pancreatic tumor. And, in images posted on the company's website, we see a patients' tumor shrinking dramatically in just 20 weeks (5 months or 1 month sooner than PharmaCyte's planned 6-month hard stop), but that was years ago when imaging wasn't nearly as good as it is today.

Imaging Endpoints will provide PharmaCyte advanced imaging that will help researchers identify biological activity during the clinical trial where traditional imaging fails. So, is there the likelihood that data will show the patients' tumors shrinking even earlier than 5 months and even more dramatically?

Experts from Imaging Endpoints will be involved in training radiologists at all of the clinical trial study sites to ensure the Cell-in-a-Box® capsules are correctly implanted into patients.

Also, Imaging Endpoints will be responsible for coordinating the data obtained from CT (computerized tomography) and PET (positron emission tomography) scans of the patients' tumors as they progress through the clinical trial. Imaging Endpoints will also analyze all of the imaging data obtained during the trial using its state-of-the-art methodology.

The table is certainly set for PharmaCyte's therapy to succeed in the clinic. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, has surrounded the technology with the brightest minds in the industry, he's obtained the orphan drug designation for the therapy, the FDA has now granted PharmaCyte a pre-IND meeting and the path to the clinic has narrowed to just getting through the final steps of the IND process. Once PharmaCyte navigates the pre-IND process and files its IND application, then the FDA will have 30 days to make comments, and if no comments are made, then PharmaCyte is effectively "approved" to begin its pivotal clinical trial in advanced pancreatic cancer.

About Stock Market Media Group

Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. PharmaCyte Biotech has not endorsed this article, and Stock Market Media Group was not compensated for its production.

Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB's filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.

For more information: www.stockmarketmediagroup.com.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor – all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
Get deep visibility into the performance of your databases and expert advice for performance optimization and tuning. You can't get application performance without database performance. Give everyone on the team a comprehensive view of how every aspect of the system affects performance across SQL database operations, host server and OS, virtualization resources and storage I/O. Quickly find bottlenecks and troubleshoot complex problems.
Internet of @ThingsExpo has announced today that Chris Matthieu has been named tech chair of Internet of @ThingsExpo 2017 New York The 7th Internet of @ThingsExpo will take place on June 6-8, 2017, at the Javits Center in New York City, New York. Chris Matthieu is the co-founder and CTO of Octoblu, a revolutionary real-time IoT platform recently acquired by Citrix. Octoblu connects things, systems, people and clouds to a global mesh network allowing users to automate and control design flo...
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Unless your company can spend a lot of money on new technology, re-engineering your environment and hiring a comprehensive cybersecurity team, you will most likely move to the cloud or seek external service partnerships. In his session at 18th Cloud Expo, Darren Guccione, CEO of Keeper Security, revealed what you need to know when it comes to encryption in the cloud.
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
With 15% of enterprises adopting a hybrid IT strategy, you need to set a plan to integrate hybrid cloud throughout your infrastructure. In his session at 18th Cloud Expo, Steven Dreher, Director of Solutions Architecture at Green House Data, discussed how to plan for shifting resource requirements, overcome challenges, and implement hybrid IT alongside your existing data center assets. Highlights included anticipating workload, cost and resource calculations, integrating services on both sides...
According to Forrester Research, every business will become either a digital predator or digital prey by 2020. To avoid demise, organizations must rapidly create new sources of value in their end-to-end customer experiences. True digital predators also must break down information and process silos and extend digital transformation initiatives to empower employees with the digital resources needed to win, serve, and retain customers.
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
The WebRTC Summit New York, to be held June 6-8, 2017, at the Javits Center in New York City, NY, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 20th International Cloud Expo and @ThingsExpo. WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web co...
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
The Internet of Things (IoT) promises to simplify and streamline our lives by automating routine tasks that distract us from our goals. This promise is based on the ubiquitous deployment of smart, connected devices that link everything from industrial control systems to automobiles to refrigerators. Unfortunately, comparatively few of the devices currently deployed have been developed with an eye toward security, and as the DDoS attacks of late October 2016 have demonstrated, this oversight can ...